NEWS
Aiforia grows presence in France
Aiforia Technologies has established a subsidiary in France to strengthen its local presence and to support its growing business in the country. The firm has had a sales organisation in France since 2023, and interest in the Aiforia’s AI-based pathology solutions has grown significantly.
France is investing heavily in the use of artificial intelligence, with healthcare being one of the key priority areas where it aims to lead industry innovations. Since 2018, the state has invested more than €2.5 billion in research, education, and accelerating the adoption of AI as part of France’s national artificial intelligence strategy. In addition, in February 2025 at the AI Action Summit in Paris, an €109 billion project was announced to invest in the country’s artificial intelligence system, including data centres. Aiforia already has a strong foothold in France; the first successful and significant collaboration with one of the world’s leading hospitals, the AP-HP hospital group in Paris in 2024, was an important strategic market opening for Aiforia. Recently, Nantes University Hospital, France’s sixth-largest hospital, also chose the company as its partner for AI-assisted pathology diagnostics.
The new subsidiary will support Aiforia’s
growth and customer service in France and enable even closer cooperation with local healthcare providers. Jukka Tapaninen, CEO of Aiforia commented: “We strongly believe that we have a significant opportunity to offer innovative solutions to the French healthcare system that improve the accuracy and efficiency of pathology image analysis and support the development of our customers’ diagnostic processes. We are confident that having a local presence is essential to offer our customers the best possible service.”
PathAI launches Precision Pathology Network
Artificial intelligence and digital pathology firm PathAI has unveiled the launch of the Precision Pathology Network (PPN), a first-of-its-kind network of digital anatomic pathology laboratories, which aims to platform expands access to latest AI products, unlock real-world data value, and fuel collaborative research with biopharma across a broad network.
The PPN is designed to enable early access to the latest AI-powered pathology solutions developed by PathAI in collaboration with the biopharma industry, enable participating laboratories to monetise real-world pathology data, support biopharma sponsored evidence generation studies, and enable novel clinical development strategies leveraging AI-pathology. The PathAI Precision Pathology Network leverages the company’s AISight IMS platform as its technological backbone and provides members: early access to AI innovations; new revenue pathways through real world data; opportunities in high- quality evidence generation studies; and the chance to accelerate therapeutic clinical development with AI-powered pathology. The Precision Pathology Network connects a diverse group of leading
healthcare and research institutions. By bringing together industry, academia, and clinical leaders in pathology, the PPN is aiming to establish a broad foundation for innovation in digital diagnostics and data- driven disease insights. “We are thrilled to launch the PathAI
Precision Pathology Network as a major step toward advancing precision diagnostics,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “PathAI is the leading digital pathology company working deeply with the biopharma industry to accelerate their precision medicine goals using AI-powered pathology, who also works with a large network of pathology laboratories who are on the cutting edge and implementing digital within their workflows. This first-of-its- kind network will play a vital role in advancing precision diagnostics and accelerating the adoption of AI in pathology.”
Partnership to advance ultrasensitive biomarker detection
Bio-Techne has announced a strategic partnership to distribute Spear Bio’s next- generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under the agreement, Bio-Techne will distribute Spear Bio’s ultrasensitive immunoassays for challenging low- abundance biomarkers, including key Alzheimer’s disease biomarkers such as phosphorylated tau 217 (pTau 217), GFAP, neurofilament light (Nf-L), and phosphorylated tau 231 (pTau 231). The initial offering will focus on key biomarkers supporting translational research in Alzheimer’s disease. This partnership follows Bio-Techne’s participation in Spear Bio’s $45 million Series A funding round in 2024. Early detection of protein biomarkers is essential for understanding historically challenging disease mechanisms,
12
developing early interventions, and advancing clinical trials. Spear Bio’s Successive Proximity Extension Amplification Reaction (SPEAR) platform, based on breakthrough technology licensed from Harvard University, and amplified using conventional qPCR instrumentation, offers sensitivity two to three orders of magnitude higher than current immunoassay platforms. “Partnering with Spear Bio marks an exciting step in our mission to advance biomarker detection in neurodegenerative disease research,” said Will Geist, President of Bio-Techne’s Protein Sciences Segment. “By leveraging Bio-Techne’s global reach and immunoassay expertise with Spear Bio’s ultrasensitive technology, we are equipping researchers with innovative tools to detect and study critical biomarkers with unmatched precision and sensitivity.”
AUGUST 2025
WWW.PATHOLOGYINPRACTICE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
